Vertex Pharmaceuticals Incorporated (VRTX) — Stock Score Summary

Vertex Pharmaceuticals Incorporated (VRTX) has a MoatMap StockRank of 84/100 based on Quality (76/100), Value (29/100), and Momentum (63/100) factor scores. The current signal is STRONG BUY. Vertex is a premier quality compounder with a virtual monopoly in cystic fibrosis and a massive cash pile to fund its next-gen pipeline (pain, diabetes, gene therapy). While not a direct CDMO, its high-margin, high-ROIC profile fits the Terry Smith lens perfectly, and its pricing power is unmatched.

Vertex Pharmaceuticals Incorporated is a biotechnology company focused on developing and commercializing transformative medicines for serious diseases, primarily cystic fibrosis (CF). It holds a dominant market position in CF treatments with proprietary, highly effective therapies that address the disease's underlying causes. Vertex is a leader in precision medicines, utilizing deep scientific expertise to target genetic mutations and expanding into other therapeutic areas.

Key Financial Metrics

Price$425.09
Market Cap$113.7B
P/E (TTM)25.84
P/E (Forward)20.30
Price/Book5.72
Return on Equity24.2%
Return on Invested Capital21.4%
Debt/Equity10.26
Gross Margin54.4%
Operating Margin38.1%
Revenue Growth7.8%
Free Cash Flow$2.8B

Vertex Pharmaceuticals Incorporated operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Vertex Pharmaceuticals Incorporated’s (VRTX) StockRank?
MoatMap’s StockRank for Vertex Pharmaceuticals Incorporated (VRTX) is 84/100, with a Strong Buy signal. It is a composite of Quality (76), Value (29), and Momentum (63) factor ranks across MoatMap’s 19,000+ stock universe.
Does Vertex Pharmaceuticals Incorporated have an economic moat?
Vertex Pharmaceuticals Incorporated (VRTX) has a Quality factor score of 76/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Vertex Pharmaceuticals Incorporated a buy, hold, or sell?
MoatMap’s current signal for Vertex Pharmaceuticals Incorporated (VRTX) is Strong Buy, based on a StockRank of 84/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Vertex Pharmaceuticals Incorporated in?
Vertex Pharmaceuticals Incorporated (VRTX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksVRTX deep dive reportAI ChampionsHow we score stocksSense-check another stock